Muscarinic receptor subtypes and the selectivity of agonists and antagonists. 1988

N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
Division of Physical Biochemistry, National Institute for Medical Research, London, UK.

Receptors may be grouped into superfamilies, according to their mechanism. Muscarinic receptors belong to one such superfamily, that of the G-protein coupled receptors. Subtypes of muscarinic receptors may be defined according to their primary amino acid sequence, their mechanism and their pharmacology. However, there is as yet no consistent scheme to explain the pharmacology and function of each molecular subtype. The pharmacological tools which distinguish between muscarinic receptor subtypes are described and the emerging evidence for the location of the ligand binding site is discussed.

UI MeSH Term Description Entries
D008455 (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride A drug that selectively activates certain subclasses of muscarinic receptors and also activates postganglionic nicotinic receptors. It is commonly used experimentally to distinguish muscarinic receptor subtypes. McN A-343,McN-A-343,McN-A343,McNeil A 343,A 343, McNeil,McN A 343,McN A343,McNA343
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010890 Pirenzepine An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients. Gastrotsepin,Gastrozepin,L-S 519,LS-519,Piren-Basan,Pirenzepin,Pirenzepin Von Ct,Pirenzepin-Ratiopharm,Pirenzepine Dihydrochloride,Pyrenzepine,Ulcoprotect,Ulgescum,Dihydrochloride, Pirenzepine,LS 519,LS519,Piren Basan,Pirenzepin Ratiopharm,Von Ct, Pirenzepin
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
February 1996, Pharmacology & toxicology,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
January 2009, The Journal of pharmacology and experimental therapeutics,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
January 2012, Handbook of experimental pharmacology,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
January 2012, Handbook of experimental pharmacology,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
January 2012, Handbook of experimental pharmacology,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
January 2012, Handbook of experimental pharmacology,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
December 1988, European journal of pharmacology,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
January 2005, Current pharmaceutical design,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
January 2012, Handbook of experimental pharmacology,
N J Birdsall, and C A Curtis, and P Eveleigh, and E C Hulme, and E K Pedder, and D Poyner, and M Wheatley
April 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Copied contents to your clipboard!